Company: LGN
Filing Date: 2025-11-03
Form Type: DRS
Source: 0001193125-25-262782
Chunk: 289

Company: Legence Corp.
Filing Date: 2025-11-03
Form: DRS
Chunk 289
---
:-------------|------:|:----|:--|-------:|
| Derivatives designated as hedging instruments Interest rate swap asset (short-term) |     | Prepaid expenses and other current assets |                        | $            | 5,861 |     | $ | 22,052 |
| Interest rate swap asset (long-term)                                                |     | Other assets                              |                        | $            | 3,387 |     | $ |  1,296 |
| Interest rate swap liability (long-term)                                            |     | Other long-term liabilities               |                        | $            |   137 |     | $ |  1,182 |

The following table presents the gross changes in AOCI from the Company’s cash flow hedges (in thousands). There was no tax impact for the years presented.

|                                                                                |     |   |    2024 |   |     |   |    2023 |   |     |   |   2022 |   |
|:-------------------------------------------------------------------------------|:----|:--|--------:|:--|:----|:--|--------:|:--|:----|:--|-------:|:--|
| Accumulated gain in AOCI at the beginning of year                              |     | $ |  22,166 |   |     | $ |  39,556 |   |     | $ |  5,051 |   |
| Unrealized gain recognized in AOCI                                             |     |   |  14,789 |   |     |   |   7,512 |   |     |   | 39,398 |   |
| (Gain) reclassified from AOCI to Interest expense, net of capitalized interest |     |   | (27,844 | ) |     |   | (24,902 | ) |     |   | (4,893 | ) |
| Other comprehensive (loss) income                                              |     |   | (13,055 | ) |     |   | (17,390 | ) |     |   | 34,505 |   |
| Accumulated gain in AOCI at the end of year                                    |     | $ |   9,111 |   |     | $ |  22,166 |   |     | $ | 39,556 |   |

For the years ended December 31, 2024, 2023 and 2022, there was no ineffectiveness recognized in earnings